Combined Detection Of Serum Biomarkers Clinical Value In The Diagnosis Of Primary Liver Cancer

Background and purpose: The AFP and AFP-L3%, GP73in healthypeople, primary liver cancer, liver cirrhosis and a variety of other patients in thecombined detection curve expression in the preliminary study in the Chinesepopulation and its diagnostic value in HCC. Expect to improve the diagnosis ofprimary liver cancer with more effective basis.Materials and methods: Blood samples of248cases were collected fromthe hospitalized patients of The First Hospital Of Jilin University betweenDecember2011and March2013, with181cases of male and67cases offemale, with age ranging from26-85years,(an average of57±10.5years).248cases were divided into4different groups： healthy control groupcomprises30cases;liver cancer group of119cases;liver cirrhosis of group71cases and28cases of group C (including7cases of hepatitis B,3cases ofhepatitis C,1case of autoimmune hepatitis,5cases of cholecystitis,9cases ofhepatic metastatic carcinoma,3cases of hepatic hemangioma). Enzyme-linkedimmunosorbent assay (ELISA) method was used to detect the expression ofAFP, GP73in the above mentioned groups. The application of AFP differentplastid affinity adsorption centrifugal tube elution for AFP-L3, computing theAFP-L3ratio in total AFP. The statistical software SPSS19.0was used toanalyse all the statistical data.Results:1) Serum AFP, AFP-L3%and GP73content of4groups werecompared by analysis of variance, the difference was statistically significant (p<0.01). AFP, AFP-L3%, GP73in HCC group was significantly higher than thecirrhosis group, group C, and the healthy group;the difference was statistically significant (p <0.01). The majority of the present study in patients with livercancer tumor diameter and the detection of serum AFP-L3%HCC tumordiameter R (s) for0.192, p <0.05, so there is a significant correlation betweenthem. The BCLC classification and AFP, AFP-L3%detection related to R (s)were0.187(p <0.05),0.2606(p <0.01).2) The AUROC of AFP, AFP-L3%,GP73for diagnosing liver cancer were0.831,0.738,0.759(p <0.01). Underthis threshold, AFP, AFP-L3%, GP73sensitivity of the diagnosis of HCC were85.7%,58.0%,69.7%and their specificity were72.9%,87.6%,76.7%.3)Using the AFP, AFP-L3%and GP73of parallel joint detection test method canimprove the sensitivity value of95.8%and the negative predictive value of93.8%. Using the AFP, AFP-L3%and GP73of series joint detection testmethod can improve the specificity value of93.8%and the positive predictivevalue of84.3%.Conclusions:1) Primary hepatocellular carcinoma patients’ serum AFP,AFP-L3%and GP73level were higher than in patients with cirrhosis andhepatitis B, hepatitis C, autoimmune hepatitis, hepatic metastatic carcinoma,liver hemangioma patients and healthy controls.2) Serum AFP-L3%level hascorrelation with hepatocellular carcinoma in patients with tumor diameter. Thelevel of serum AFP-L3%was more elevated, the tumor diameter was larger.3)the serum AFP, AFP-L3%level has correlation with BCLC classification. Thelevel of serum AFP, AFP-L3%was more elevated, the patients with BCLCstage is at greater risk.4) AFP and AFP-L3%, GP73which can be used asserum biomarkers for diagnosis of liver cancer, the three joint detection withhigher sensitivity, can improve the rate of diagnosis of liver cancer.